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Genetic Polymorphisms that 
Playing Role in Development of 
Hypertrophic Cardiomyopathy
Nevra Alkanli and Arzu Ay
Abstract
Hypertrophic cardiomyopathy (HCM) is a complex heart disease with various 
physiopathological, morphological, functional, and clinical features. In this disease, 
HCM is known to be an autosomal genetic disease in more than half of the cases. 
Mutations in sarcomeric genes are thought to play an important role in the patho-
genesis of the disease. Modifying genes and environmental factors also together 
affect the phenotypic expression and severity of HCM. The phenotypic expression 
of HCM is determined by causal sarcomeric gene mutations and the regulatory 
genetic basis of genes. HCM, a multi-factorial disease, involves the effects of many 
environmental gene modifiers and the sarcomeric/cytoskeletal genes. The single 
nucleotide polymorphisms occurring in the human genome differ in terms of sus-
ceptibility to disease in various populations. Therefore, the determination of genetic 
polymorphisms involved in the development of HCM disease is very important for 
the diagnosis of the disease.
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1. Introduction
HCM is a complex cardiac disease with major clinical heterogeneity and diag-
nostic and prognostic effects specific to each mutation. At the same time, this 
disease has different physiopathological, morphological, functional, and clinical 
features. HCM, with left ventricular hypertrophy (LVH), is a primary cardiac 
disorder and occurs when there is no cardiac or systemic disease. Throughout 
life, it is known that it has a clinical course ranging from symptomatic patients to 
heart failure symptoms and sudden deaths. It is an autosomal dominant genetic 
disease in more than half of cases, but it still does not have a fully defined etiol-
ogy [1]. Modifying genes and environmental factors play an important role in the 
pathogenesis of HCM. Phenotypic expression and the formation of cardiovascular 
events are affected by means of these factors [2]. The cardiac β-myosin heavy chain 
(MYHC) gene, cardiac troponin T (cTnT) gene, α-tropomyosin gene, myosin-
binding protein C (MYBP-C) gene, cardiac troponin I gene, and regulatory and 
essential myosin light chain genes are found among genes encoding the proteins of 
sarcomere [1]. These genes encoding sarcomeric proteins are localized on differ-
ent chromosomes. It is known that the first gene identified from these genes is 
the βMYHC gene encoding the major contractile protein. In HCM patients, due to 
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defects in sarcomeric proteins, mutations such as MYBP-C, α-tropomyosin, cTnT, 
ventricular myosin essential and regulatory light chains, cardiac troponin I, and 
cardiac α-actin and titin have been described. This disease, known to be caused by 
the defects in sarcomeric proteins, is called sarcomere disease [3]. In addition to 
mutations in sarcomeric and non-sarcomeric genes, many other gene mutations 
also lead to metabolic disorders with similar phenotypes in HCM [4]. So far, more 
than 1400 mutations have been identified in many genes, and the most important 
genes of these mutations have been identified to encode the protein components of 
cardiac sarcomere that perform contractile, structural, and regulatory functions 
[5]. The purpose of this chapter, in addition to giving general information about 
HCM, is to summarize the studies that investigated the relationship between gene 
polymorphisms that play a role in the development of HCM and the risk of develop-
ing HCM.
2. Hypertrophic cardiomyopathy
HCM, a cardiac disease, is characterized by marked hypertrophy and genetic 
variability. It is known as a disease characterized by LVH which may cause 
primary or systemic hypertrophy when there is no other disease [6]. LVH, known 
as a physiological adaptation to increased workload of the heart, usually develops 
in clinical conditions such as hypertension, valvular disease, and myocardial 
infarction. In some patients, cardiac hypertrophy develops when there are no 
clinical conditions causing cardiac overload. This condition is considered to be the 
basic form of LVH, and it is thought that this form, which is frequently familial, is 
caused by mutations in sarcomeric genes. This form of the most common heredi-
tary heart disease is defined as HCM [7]. HCM is one of the leading causes of 
sudden deaths in young people and athletes. One person in 500 people worldwide 
is affected by this disease [6]. HCM is a common heterogeneous disease with high 
morbidity and mortality in the elderly, and it is characterized by enlarged heart, 
abnormally thickened left ventricular walls, and reduced chamber capacity [8]. 
Histologically, in this disease, characterized by left ventricular thickness resulting 
from cardiomyocyte hypertrophy, cardiomyocytes lose their cleavage ability in 
the first week after birth. Thus, cardiomyocyte hypertrophy is effective instead of 
cardiomyocyte proliferation in postnatal growth of the heart. Postpartum cardiac 
growth is a physiological response of myocardium to stress signals as well as its 
role in cardiomyocyte hypertrophy. It is known that the response of cardiomyo-
cytes to stress signals is characterized by reactivation of fetal gene program [4]. 
This disease is thought to be caused by contractile proteins encoding genes that 
cause contractile dysfunction and then hypertrophy. Familial HCM, defined as 
an autosomal dominant disorder, is usually disseminated by incomplete pen-
etrance due to heterozygous pathogenic gene mutations [8]. HCM is a genetically 
transmitted, cardiovascular disease with heterogeneous clinical features. Sudden 
cardiac death in HCM occurs as a frequent complication of 2–3% per year. HCM 
can be seen form of autosomal dominant feature as a familial disorder; on the 
other, it can also occur as a sporadic disease that may develop due to novo muta-
tions. These familial and sporadic forms represent different parts of the same 
spectrum. According to phenotypic models, HCM phenotypes, asymmetric septal 
hypertrophy (ASH), apical hypertrophy (AH), diffuse hypertrophy (DH), and 
left ventricular free wall hypertrophy (FH) are classified as. The etiology of the 
disease is multifactorial, and the majority of cases occur due to secondary muta-
tions in sarcomere myofilament genes. The sarcomere myofilament genes are 
genes that contribute to heterogeneity in the phenotype of the disease. HCM has a 
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wide familial variability ranging from severe symptomatic individuals to asymp-
tomatic individuals [4]. Cardiac phenotype and variability in clinical course not 
only depend on pathogenic genes but also depend on environmental factors [3]. 
Important information can be obtained in terms of prognosis and treatment 
of the disease through the identification of these environmental and genetic 
factors [4].
3. Genetic polymorphisms
3.1 Sarcomeric gene polymorphisms
3.1.1 βMYHC versus MYBP-C gene polymorphisms
Mutations in cardiac β-myosin encoded by the MYH7 gene and myosin-binding 
protein C sarcomere proteins encoded by MYBC3 gene have been associated with 
the development of HCM disease. Mutations in these genes are responsible for 
50–70% of HCM’s genetic cases. β-myosin is a large protein containing 1935 amino 
acids and is localized on chromosome 14 (14q11) in human. During muscle contrac-
tion 2q13 interacts with the thin filament, and this gene consists of 40 exons. The 
MYBP-C gene is also localized on chromosome 11 (11p.11.2), and 14 mutations have 
been identified in this gene so far. It has been reported that four of these mutations 
to be caused by nucleotide changes and eight of which by truncated mutations. 
The most important feature of these mutations is moderate hypertrophy and low 
penetration until a certain period of life. About 40 mutations have been identified 
in β-MYHC that may cause disease, and it is known that most of these mutations 
occur as a result of the translocation of DNA nucleotides. Displacement in nucleo-
tides also causes amino acid changes in the protein sequence. This change is particu-
larly observed in the familial form of HCM. Among these 40 mutations, there are 
mutations with high, medium, and low sudden death risks. Arg403Gln, Arg453Cys, 
and Arg719Gln mutations are known to be malignant. Arg403Gln-related pheno-
types were observed in many families, and it is determined that these phenotypes 
were associated with high penetrance, high incidence of sudden death, and severe 
hypertrophy. Glu930Lys and Arg249Gln polymorphisms were associated with the 
middle risk of sudden death. However, Leu908Val, Gly256Glu, Val606Met, and 
Fhe513Cys polymorphisms have been reported to be associated with benign prog-
nostic and normal survival. Myosin, a hexameric protein, consists of two heavy and 
two light chains. Light chains contain two light chains as the regulatory light chain 
(RLC) and the basic light chain (ELC). The myosin heavy chain is also divided into 
three parts as the lower part 1 (S1), the lower part 2 (S2), and the light meromyosin 
(LMM). Regulatory and essential myosin light chains were first found in 1996. The 
regulatory MYL2 gene is localized on chromosome 12 (12q23-q24.3). The essential 
gene is localized on chromosome 3 (3p) [1]. A large number of mutations have been 
identified in most S1 and S2 regions, which are associated with HCM in the MYH7 
gene. The frequency of these mutations is variable and is known to be associated 
with marked hypertrophy. MYH7 and MYBPC3 genes are responsible for about 
70% of genotyped HCM cases. Mutations in the MYH7 gene are missense mutations 
and localized at the head of globular myosin. The MYH7 gene is also known to be 
associated with dilated cardiomyopathy, and a large number of mutations have been 
identified in the rod region of the gene. There are many studies that demonstrate 
a relationship between mutations in the MYH7 gene and the family history of 
HCM. Studies to investigate MYH7 mutations have generally been limited by the 
analysis of regions encoding the head and neck domains of βMYHC. However, it is 
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determined that mutations in the tail region of the protein may be related to the risk 
of developing HCM. Mutations in the MYH7 gene are known as a cause of HCM, 
and sudden death was significantly higher in the family history and in patients with 
severe left ventricular hypertrophy. In a previous study, four new mutations are 
identified. In some of these mutations, the relationship between genotype and phe-
notype is constant. There are significant differences between phenotypes in other 
mutations [9]. In a study conducted with the Venezuelan population, no missense 
mutation identified in the MYH7 gene was found. In the same study, the frequency 
of mutation of MYH7 gene in adult HCM patients was found to be low. In another 
study performed by Ronkaratti et al., in the Italian population, it is found that the 
frequency of mutations determined in the MYH7 gene was found to be very low. 
Many factors, such as modifying genes, epigenetic factors, microRNAs, posttrans-
lational protein modifications, and environmental factors, may affect the clinical 
course of HCM disease [1, 10]. Genetic studies are required to understand the clini-
cal and prognostic heterogeneity of HCM. The obtained information of clinical and 
morphological characteristics of different mutation carriers is important in terms of 
clinical decision-making in their genetic studies [9].
3.1.2 Cardiac troponin T gene polymorphisms
The cardiac troponin T gene is localized on chromosome 1 (1q3), and so far eight 
mutations have been identified in this gene. The most important feature of these 
mutations is that they cause hypertrophy and high incidence of sudden death in 
younger patients under 30 years of age [1].
3.1.3 Alpha tropomyosin gene polymorphisms
Alpha tropomyosin gene is localized on chromosome 15 (15q2), and two muta-
tions of this gene have been observed to date. It is observed in a low proportion of 
HCM cases and is known to be associated with normal survival [1].
3.2 TLR4 gene polymorphisms
Studies have shown that the immune system and multiple proinflammatory fac-
tors play an important role in the pathogenesis of HCM. Toll-like receptor 4 (TLR4), 
a member of the pattern recognition receptors, plays an important role as mediation 
in inflammatory response. TLR4 consists of three exons involved in immunoregu-
lation and is localized in region 9q32-q33. It acts by suppressing T lymphocyte 
proliferation and regulating macrophage function. The lack of TLR4, which is 
known to play an important role in the development of cardiovascular diseases, has 
been reported to be associated with doxorubicin-induced cardiomyopathy in mice. 
A significant relationship between abnormal expression or genetic polymorphisms 
and cardiovascular remodeling, which is considered to be an important risk factor 
for metabolic syndrome, has been found. TLR4, which can trigger protein kinase 
signaling and innate immune response active with mitogen, leads to activation of 
proinflammatory cytokines and Chemokines. Common polymorphisms in the TLR4 
gene are the rs4986791 and rs4986790 polymorphisms. In addition to these poly-
morphisms, new polymorphisms have been identified in the promoter region and in 
the 3′ untranslated region (3′-UTR) of TLR4. Even if the polymorphisms occurring 
in the promoter region do not alter the gene’s coding sequence, the initiation of gene 
transcription is affected when these gene polymorphisms lead to pathogenicity. 
Cohort studies aimed at determining the relationship between cardiovascular dis-
eases and TLR4 gene polymorphisms were performed, and inconsistent results were 
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obtained in these studies. In a study by Lindstrom et al., TLR4 gene polymorphisms 
were associated with decreased risk of prostate cancer. In another study by Castano 
et al., TLR4 was found to be associated with increased gastric cancer risk in the 3′-
UTR region. In a study by Kiechl et al., it was concluded that TLR4 gene polymor-
phisms were associated with heart diseases such as atherogenesis. No large number 
of studies have been carried out to determine whether TLR4 gene polymorphisms 
are genetic risk factors for HCM. In a study conducted with the Han-China popula-
tion, TLR4 gene polymorphisms were found to be genetic risk factors in the devel-
opment of HCM. In this study, it was determined that rs11536865 and rs10983755 
gene polymorphisms in the promoter region of the TLR4 gene are important risk 
factors for HCM development. In this study, the potential relationships of TLR4 
gene polymorphisms with the sensitivity and prognosis of HCM have been revealed. 
It is determined that it is associated with decreased plasma TLR4 levels of the GG 
genotypes of −728G > C polymorphism and GG genotypes of −2081G > A polymor-
phism in HCM patients. However, the C allele of the −728G > C polymorphism and 
the A-allele of −2081G > A polymorphism were found to be related to the highest 
plasma TLR4 levels. Inflammation and innate immunity are also contributed to 
the development of cardiomyopathy. Accordingly, it is believed that TLR4 gene 
polymorphisms affect the progression of natural immunity or inflammation, thus 
altering the expression level of TLR4, which is involved in the development of 
HCM. When studies with larger populations are performed, different results are 
likely to occur [8]. Primer sequences for −728G > C and −2081G > A gene polymor-
phisms are presented in Table 1.
3.3 HOPX gene polymorphisms
Homeodomain only protein x (HOPX) is a homeodomain protein that regulates 
the serum response factor (SRF)-dependent gene expression. In addition, HOPX 
is thought to play a role as tumor suppressor gene in some tissues, and expression 
is silenced in human carcinomas such as choriocarcinoma, lung cancer, head and 
neck squamous carcinoma, and esophageal cancer during cardiac hypertrophy, SRF 
activity, which controls the transcription of genes, including cellular immediate-
early genes, and cell skeletal and contractile proteins, is controlled by cofactors 
such as myocardium and compressors such as HOPX. The expression of the HOPX 
gene encoding a homeodomain protein is under the control of the two promoter 
regions. One of these promoters is regulated by the cardiac-specific transcription 
factor Nkx2–5. The HOPX gene plays a role as SRF antagonist, and it is effective in 
prenatal cardiomyocyte proliferation and postnatal cardiomyocyte hypertrophy. 
This antagonistic effect performed through by the take of histone deacetylase. In 
addition, HOPX is thought to play a role as tumor suppressor gene in some tissues, 
and expression is silenced in human carcinomas such as choriocarcinoma, lung can-
cer, head and neck squamous carcinoma, and esophageal cancer. HOPX has a role 
coactivator on SRF activity. Through this, it plays an active role in cardiac hypertro-
phy. HOPX gene expression is known to be downregulated in kalp insufficiency, but 
SNPs Forward primer (5′–3′) Reverse primer (5′–3′)
−728G > C 5′-TGATAGACCCCACAACTCCT-3′ 5′-TGATTTCCCCC- CATAGGATG-3′
−2081G > A 5′-TACCACCACTGTTCGCTCAG-3′ 5′-GGTTATGAGGGACATTGGAT-3′
PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
Table 1. 
Primer sequences used in PCR for TLR4 gene polymorphisms.
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the association between gene polymorphisms in the HOPX gene and heart disease 
such as heart failure or HCM has not been well established. HOPX protein is not a 
component of sarcomere and plays a role as a modifying gene. In a study investigat-
ing the relationship between HOPX gene polymorphism and SRF-dependent gene 
expression, it was determined that the expression decreased in heart muscles of 
mutant mice. Sequence variations in the HOPX gene in particular in the regulatory 
region have been shown to be associated with HCM. The relationship between 
HOPX and syncope in HCM is classified in two ways as dependent on SRF and 
independent on SRF. The HOPX gene plays a modifying role in HCM pathogenesis 
through SRF-dependent genes, and it is thought that the modifying effect may be 
more pronounced in patients with mutations in target genes. In a previous study 
performed in HCM patients, no mutation was detected in the coding sequence 
of the HOPX gene, but two noncoding polymorphisms associated with syncope 
were detected. In these polymorphisms, it is determined that homozygous states 
are protective against syncope and heterozygote cases are a genetic risk factor for 
syncope. The epigenetic status and genetic variations of the HOPX gene are impor-
tant as modifying factors in HCM [4]. Primer sequences for HOPXe1, HOPXe2, and 
HOPXe3 gene polymorphisms are presented in Table 2.
3.4 PRKHC gene polymorphisms
The PRKCH gene is a susceptibility gene that plays an important role in atheroscle-
rotic diseases such as cerebral infarction and is associated with the development and 
progression of atherosclerosis in humans. This gene encodes protein kinase C (PKC), 
and PKC is activated by diacylglycerol which calcium and secondary messenger. Protein 
kinase C (PKC) functions as an important signal transduction pathway in the develop-
ment of cardiac hypertrophy, and studies performed with cell culture and animal mod-
els explain this function. It is serine-threonine kinase which is effective in regulating 
various important cellular functions including proliferation, differentiation, and apop-
tosis. Members of the PKC family which phosphorylate a wide variety of protein targets 
are associated with several signalization pathways. There are studies showing that PKC 
activation is important in the pathology of cardiovascular diseases. The PRKCH gene is 
located in the ATP-binding region of PKCη in exon 9. PKCη, expressed in the skin and 
heart tissues, is effective by the way of contributing to cellular processes such as prolif-
eration, differentiation, secretion, and apoptosis. PKCη also plays an important role in 
immune functions such as regulation of TLR2 responses in macrophages, T-cell prolif-
eration, and homeostasis. The 1425G/A (Val374Ie) polymorphism in the PRKCH gene 
localized on 14q22-q23 in human increases the kinase activity. In a study conducted 
by Centurione et al., PKCη has been reported to regulate hypertrophic and apoptotic 
events, NF-Kb signaling system, and intrinsic mitochondrial apoptotic pathway in rat 
neonatal heart. In a study conducted with a Chinese population, the PRKCH 1425G/A 
gene polymorphism was found to be a genetic risk factor in the development of hyper-
trophic obstructive cardiomyopathy (HOCM). In studies conducted with Chinese and 
SNPs Forward primer (5′–3′) Reverse primer (5′–3′)
HOPXe1 5′-AACGTGCTATCAGCAGCCTG-3′ 5′-GACGAACAGGACCGCCCAGC-3′
HOPXe2 5′-CGACCGCCTTCCTTCGCTGC-3′ 5′-CCTTCATGGAGTGAAGCTGTC-3′
HOPXe3 5′-CTTGTGCCACAGAGGCTACC-3′ 5′-CCTTCATGGAGTGAAGCTGTC-3′
PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
Table 2. 
Primer sequences used in PCR for HOPX gene polymorphisms.
7Genetic Polymorphisms that Playing Role in Development of Hypertrophic Cardiomyopathy
DOI: http://dx.doi.org/10.5772/intechopen.83473
Japanese populations, PRKCH 1425G/A gene polymorphism was found to be associated 
with increased ischemic stroke and the risk of cerebral hemorrhage. More studies 
should be performed related to molecular mechanisms to determine the relationship 
between the risk of developing PRKCH and HOCM [5]. Primer sequences for PRKCH 
1425G/A gene polymorphisms are presented in Table 3.
3.5 SCN10A gene polymorphisms
The SCN10A gene encodes NaV1.8, a neuronal sodium channel isoform. NaV1.8 
is an alpha subunit of sodium channels with voltage door. NaV1.8 localized in the 
peripheral nervous system is associated with chronic and neuropathic pain. With rapid 
and sustained stimulation, long-term action potential is observed and excitability is 
maintained. SCN10A identified in the human heart was found to be associated with 
changes in cardiac and atrioventricular conduction. Significant relationships were 
found between the PR interval, QRS duration, and SCN10A gene polymorphisms in 
recent genome-wide association studies. Starting from this, it is concluded that NaV1.8 
plays an important role in cardiac electrophysiology. In a study by Chambers et al., 
rs6795970 gene polymorphism has been shown to result in the amino acid exchange 
A1073V in the IDII/III intracellular cycle of NaV1.8. In another study, it was deter-
mined that the A-allele of the rs6795970 gene polymorphism occurring in the SCN10A 
gene may be related to the cardiac conduction abnormalities observed in HCM 
patients. In addition, significant correlations were found between the A-allele of the 
rs6795970 gene polymorphism and the increase in the risk of first-degree heart block, 
bundle brunch block, and bifascicular heart block [2].
3.6 HSP 70 gene polymorphisms
Heat shock protein 70 (HSP 70) is localized on 6p21.3 and is located in the class 
III region of the major histocompatibility complex (MHC). This gene is expressed 
in response to heat shock and stress stimulators such as oxidative free radicals 
and toxic metal ions. Some of the HSPs play an important role in controlling 
protein folding, translocation, or degradation and are structurally expressed in 
non-stressed cells. There are three gene modifiers such as HSP 70-1, HSP 70-2, and 
HSP 70-Hom. HSP 70-1 and HSP 70-2 are those that encode an identical protein 
of the heat-inducible HSP 70. HSP 70-Hom is expressed at structurally low levels; 
it encodes a protein non-inducible with heat. There are studies showing that the 
overexpression of heat shock proteins has a cardioprotective role and that genetic 
variants of HSP 70 may reduce the ability of cells to protect against ischemia. The 
genetic polymorphisms in the HSP 70 gene have been found to play an important 
role in various diseases such as Parkinson’s disease, schizophrenia, breast carci-
noma, ischemic stroke, and coronary artery disease. The relationship between HSP 
70 specific genotypes and hypertrophic cardiomyopathy has not been reported so 
far. In a previous study, the modifying role of HSP 70 has been described. In the 
study, it was found that HSP plays a regulatory role in HCM-related inflammatory 
SNPs Common primer (5′–3′) Allele-specific primer (A)
Allele-specific primer (G)
PRKCH
1425G/A
5′-GCAGAATCACGTCCTTC 
TTCAG-3′
5′-CATAGGTGATGCTTGCAAGAA-3′
5′-CATAGGTGATGC TTGCAAGAG-3′
PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
Table 3. 
Primer sequences used in PCR for PRKCH gene polymorphism.
Practical Applications of Electrocardiogram
8
responses and hemodynamic compensatory mechanisms. HSP genes are genes that 
encode a family of structurally produced proteins in the fulfillment of basic func-
tions, which increase expression in response to various metabolic stimuli. One of 
the most important tasks of these genes is to facilitate the synthesis and folding of 
proteins within the cells. In addition HSP genes play an important role in protein 
binding, secretion, protein degradation, and in the regulation of protein kinases via 
transcription factors. Polymorphisms in the expression of HSP genes are controlled 
by a number of transcription factors, and these factors are called heat shock factors 
(HSF). As a result of the increase and accumulation of HSPs, the protection of the 
stressed cell is increased; thus the cell survival is maintained. Overexpression of 
HSP 70 elicits its cardioprotective property. As a result of the polymorphisms occur-
ring in the HSP 70 gene, the synthesis of HSP 70 protein can be changed [11].
3.6.1 HSP 70-1 (+190G/C) polymorphism
The HSP 70-1 (+190G/C) polymorphism is a silent polymorphism of the initial 
domain translated in the 5′-UTR region of the gene. It has been reported to be a 
significant relationship between this polymorphism and various diseases such as 
Parkinson’s disease, high-altitude illness, and diabetes mellitus. HSP 70 is known as 
a significant stress protein whose production is increased under stress [11].
3.6.2 HSP 70-2 (+1267A/G) polymorphism
The HSP 70-2 (1267A/G) polymorphism is a polymorphism located in the coding 
region of the gene. HSP 70-2 changes the expression of mRNA, and the relation-
ship between this expression and the +1267A/G polymorphism is shown in several 
studies. In a study, G allele of HSP 70-2 (1267A/G) polymorphism was found to be 
an important risk factor in the development of HCM. In a study by Pociot et al., 
it was determined that the differences between individuals in HSP 70 expression 
may be related to different regulatory mechanisms than transcriptional regulation. 
In addition, the HSP 70 polymorphic region affects expression and enzyme activ-
ity of the synonymous gene polymorphism. As a result of changing the timing of 
co-translational folding, the secondary structure of mRNA, stability, substrate, 
or inhibitor binding sites of the brain vary. In a study, there was no change in the 
secondary structures of the A and G alleles of HSP 70-2 mRNA [11].
3.6.3 HSP 70-Hom (+2437C/T) polymorphism
The HSP 70-Hom (+ 2437C/T) polymorphism is characterized by the Met493Thr 
missense translocation, which affects the substrate specificity and chaperone activ-
ity of HSP 70-Hom. In a study conducted with a Mexican population, a significant 
relationship was found between the +2437 T allele and spondyloarthropathies of 
HSP 70-Hom (+ 2437C/T) gene polymorphism. It is known that nucleotide changes 
in the coding region may influence the peptide binding kinetics and the affinity of 
ATPase activity with HSP 70 proteins. Furthermore, as a result of the nucleotide 
changes that occur in the side regions, the inducibility, expression grade, and stabil-
ity of mRNA can be affected. Overexpression of HSP 70 is a preservative against the 
damaging effects of ischemia. In consequence of excessive expression, the release 
of the creatine kinase of the heart, recovery of high-energy phosphate depots, and 
correction of metabolic acidosis are performed. Protective effects of HSP include 
protein folding, abnormal protein degradation, inhibition of apoptosis, preserva-
tion of the cell skeleton, and improved NO synthesis. Apoptosis, a programmed 
cell death involving the release of cytochrome c, is an important consequence of 
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hypertrophy decompensation. HSP 70 expression and activation of procaspase 9, 
leading to cardiac hypertrophy, can inhibit caspase-mediated apoptosis activity. 
Hence, the expression of HSP proteins is affected by HSP 70 genes and polymor-
phisms in these genes. Thus, the ability to inhibit apoptosis resulting in HCM due 
to cardiac hypertrophy may be affected. In a previous study, the C allele of the HSP 
70-1 gene polymorphism and the G allele of the HSP 70-2 gene polymorphism 
were found to be associated with increased risk of HCM [11]. Primer sequences for 
HSP-70-1 +190G/C, HSP-70-2 −1267A/G, and HSP-70-hom −2437T/C gene poly-
morphisms are presented in Table 4.
3.7 RAAS gene polymorphisms
The renin-angiotensin-aldosterone system (RAAS) can cause ventricular 
hypertrophy through circulating angiotensin. RAAS plays an important role in cell 
proliferation, regulation, and the partial expression of heart hypertrophy, thereby 
developing LVH [3]. It is also known to play a regulatory role in cardiac function, 
blood pressure, and electrolyte homeostasis in the body. Angiotensinogen (AGT), 
renin, angiotensin-converting enzyme (ACE), and angiotensin II receptors of 
RAAS are found in the heart, and these components function more independently 
than circulating RAAS [7]. Angiotensin I is converted to angiotensin II through 
ACE, and angiotensin II is linked to type 1 receptor angiotensin II (AGTR1). 
Angiotensin II has an important role in supporting cell growth and hypertrophy. 
In addition, angiotensin II is converted to aldosterone by aldosterone synthase 
(CYP11B2), and aldosterone supports cardiac fibrosis. Aldosterone plays an impor-
tant mediator role in HCM, among sarcomeric mutations and cardiac phenotypes 
[12]. RAAS activation or receptor function may increase as a result of genetic 
polymorphisms in genes encoding RAAS. In some studies, a significant relation-
ship was found between RAAS gene polymorphisms and increased hypertrophic 
response against HCM. In some studies, RAAS gene polymorphisms have been 
found to be genetic risk factors in the development of LVH, but there are studies 
that have not confirmed this. Childhood HCM is an early onset HCM and it shows 
a rapid progress. Furthermore, a growing heart shows more dependence on RAAS 
than the adult heart. Therefore, it is thought that the growing heart may be more 
sensitive to RAAS gene polymorphisms. Although studies have shown that there 
is a relationship between RAAS and HCM, in some studies with different popula-
tions, the role of RAAS in the change of HCM phenotype is not well-known [7]. It 
is thought that modifier genes that regulate RAAS may alter the responses to drug 
therapies and hence may be effective in the prognosis of HCM patients. RAAS, 
which is known to be associated with hypertrophy in familial HCM, has been 
shown to be more effective in sporadic HCM. Early diagnosis of genetic risk factors 
such as RAAS gene polymorphisms in terms of risk classification and development 
SNPs Forward primer (5′–3′) Reverse primer (5′–3′)
HSP 70-1 
+190G/C
5′-CGCCATGGAGACCAACACCC-3′ 5′-GCGGTTCCCTGCTCTCTGTC-3′
HSP 70-2 
−1267A/G
5′-CATCGACTTCTACACGTCCA-3′ 5′-CAAAGTCCTTGAGTCCCAAC-3′
HSP 70-hom 
−2437T/C
5′-GTCCCTGGGGCTGGAGACG-3′ 5′-GATGATAGGGTTACACATCTGCT-3′
PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
Table 4. 
Primer sequences used in PCR for HSP 70 gene polymorphisms.
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of new strategies for interventions to individual according to this classification are 
very important [13].
3.7.1 ACE gene polymorphisms
ACE increases the synthesis of angiotensin II by inducing cell proliferation, 
migration, and hypertrophy. Angiotensin II develops the proinflammatory 
cytokines and matrix metalloproteinases. Therefore, overexpression of angio-
tensin II is thought to play an important role in cardiomyopathy. ACE, which 
converts angiotensin I to angiotensin II, functions as a growth factor for cardiac 
myocytes. It has been reported to induce the cardiac hypertrophy independent 
of hemodynamic and neurohumoral effects. The ACE gene is localized on 
chromosome 17 (17q23.3) in the human genome. The gene, which is 21 kilobase 
in length, consists of 26 exons. The ACE insertion/deletion (I/D) gene polymor-
phism corresponds to a repetitive sequence of 287 base pairs (Alu) in intron 16. 
DD genotype of ACE (I/D) gene polymorphism was found to be associated with 
increased ACE and angiotensin II levels. This causes increased hypertrophy and 
fibrosis. Phenotypic expression of HCM is also affected as a result of increase 
of angiotensin II levels. Previous studies have shown a significant relationship 
between ACE (I/D) gene polymorphisms and plasma angiotensin II levels. 
ACE (I/D) gene polymorphism has been shown to modulate the phenotype in 
HCM patients. In studies conducted with different populations, contradictory 
results were found in terms of the relationship between ACE (I/D) gene poly-
morphisms and the risk of developing HCM. In a study performed in Japanese 
population by Yamada et al., no significant relationship was found between 
ACE (I/D) gene polymorphism and HCM. In a study by Perkins et al., it was 
determined that the DD genotype of the ACE (I/D) gene polymorphism was 
important in the phenotypic expression of HCM and the ACE tissue levels were 
higher in patients with DD genotype. In another study carried out by Schunkert 
et al., a significant association was found between D allele of the ACE (I/D) 
gene polymorphism and increased LVH in HCM patients. In a study conducted 
by Rai et al., in the Indian population, ACE (I/D) gene polymorphism was found 
to be a genetic risk factor for HCM and dilated cardiomyopathy. In a meta-
analysis study, D allele of ACE (I/D) gene polymorphism has been reported to 
be associated with increased risk of HCM. In patients with HCM that carry the 
DD genotype of the ACE (I/D) gene polymorphism, higher serum ACE levels, 
increased risk of sudden death, and higher severity of hypertrophy are observed 
than other genotypes. Angiotensin II, which shows trophic effects on the heart, 
also plays an important role in the development of myocardial hypertrophy. The 
AGTR1 antagonist has an important role in reducing myocardial hypertrophy, so 
it may be an important treatment option to prevent the sudden cardiac death in 
patients with HCM. It is thought that obtaining different results in the studies 
is due to differences in research design, environmental backgrounds, genetic 
structure, or sample selection criteria in studies. Further genome-wide relation-
ship studies are needed to determine the relationship between the ACE gene and 
HCM [3, 7].
3.7.2 AGTR1 and AGTR2 gene polymorphisms
LVH is known to be variable in patients with HCM. Angiotensin II plays an 
important role in the change of LVH. AGTR1 A1166C and angiotensin II type 
2 receptor (AGTR2). As a result of A3123C gene polymorphisms, phenotypic 
expression of hypertrophy in HCM is affected. The AGTR1 gene is localized on 
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chromosome 3q21. AGTR1 A1166C gene polymorphism is characterized by adenine 
(A)/cytosine (C) base translocation at position 1166 of the gene. Different results 
have been obtained in studies attempting to explain the relationship between these 
gene polymorphisms and HCM development [12].
3.7.3 CYP11B2 gene polymorphisms
It has been determined that aldosterone, which can be produced locally 
in the heart, is associated with sarcomeric mutations and cardiac phenotype. 
The CYP11B2 −344C/T gene polymorphism is characterized by C/T base 
displacement at the −344 position of the CYP11B2 gene localized on the 8q22 
chromosome. The CYP11B2 gene polymorphism was found to be associated 
with left ventricular mass in human essential hypertension. In a previous study, 
aldosterone was found to modify the phenotypic expression of the mutated gene 
in HCM. A significant relationship between CYP11B2 genotype and cardiac 
hypertrophy has been shown in HCM. It has also been reported that the T allele 
of the CYP11B2 gene polymorphism in patients with essential hypertension 
has been identified as a genetic risk factor for left ventricular mass. In another 
study, a significant association was found between the CYP11B2 −344C/T gene 
polymorphism CC genotype and cardiac hypertrophy among healthy controls 
[14]. Several previous studies have reported that the T allele of the CYP11B2 gene 
polymorphism is associated with increased plasma aldosterone levels. Therefore, 
it is thought to be a significant relationship between T allele of this gene 
 polymorphism and cardiac hypertrophy [12].
3.7.4 AGT gene polymorphisms
AGT released into the circulation is a glycoprotein produced by hepatocytes 
containing 485 amino acids. It is known that AGT is converted into angiotensin 
I by the renin enzyme. The rate in angiotensin production plays a role in the 
regulation of AGT concentration and angiotensin II production. In addition, 
AGT plays an important role in essential hypertension, renal tubular dysgenesis, 
non-familial structural atrial fibrillation, and in LVH via strong myotrophic 
effect. The AGT gene is known to regulate the expression of AGT. AGT M235T 
gene polymorphism is characterized by methionine/threonine base displace-
ment in chromosome 1q42 of the AGT gene [14]. In studies conducted to 
investigate the relationship between AGT M235T gene polymorphism and HCM, 
controversial results were found. Although in some studies significant relation-
ships were determined, in some studies were not found. In a study conducted 
with the Japanese population by Kawaguchi et al., it was determined that TT 
genotype and T allele of the AGT M235T gene polymorphism were genetic risk 
factors for HCM. However, in the same study, no significant relationship was 
found between TT genotype and T allele of this gene polymorphism and familial 
form of HCM. A higher T allele frequency was found in patients with sporadic 
HCM. The TT genotype of the AGT M235T gene polymorphism is thought to 
be a genetic marker for LVH. It was also found to be significant relationship 
between this polymorphism and other cardiovascular diseases such as myocar-
dial infarction, coronary atherosclerosis, and hypertension. In another study 
conducted with the South Indian population, the relationship between T704C 
gene polymorphism and HCM in exon 2 of the AGT gene was investigated. In 
this study, T allele of AGT T704C gene polymorphism was found to be associ-
ated with sporadic HCM. However, it was concluded that this allele is not a 
genetic risk factor for familial HCM. In conclusion, the T allele of the AGT 
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T704C gene polymorphism has been reported to be associated with the develop-
ment of sporadic HCM. A larger scale of cohort studies should be performed 
to confirm the relationship between T alleles and HCM development of these 
gene polymorphisms [3]. Primer sequences for RAAS gene polymorphisms are 
presented in Table 5 [15, 16].
4. Conclusions
It is known that genetic and environmental factors play a role in the patho-
genesis of HCM. Numerous studies have been conducted to investigate gene 
polymorphisms playing the role in HCM development. The differences in the 
results of these studies are thought to be stemmed from different race and 
population characteristics and different selection criteria of patient and con-
trol groups in the study. The identification of genes and the polymorphisms 
occurring in these genes that are effective in the development of HCM will 
enable us to have knowledge about disease-related mechanisms in HCM sus-
ceptibility and to develop new drug and treatment strategies in the prevention 
of HCM. Different results can be obtained in studies with different and larger 
populations.
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SNPs Forward primer (5′–3′) Reverse primer (5′–3′)
ACE (I/D) 5′-CTGGAGAGCCACTCCCATCCTTTCT-3′ 5′-GACGTGGCCATCACATTCGTCAGAT-3′
AGTR1 
A1166C
5′-GAAGCCTGCACCATGTTTTGA-3′ 5′-GGCTTTGCTTTGTCTTGTTG-3′
CYP11B2 
−344C/T
5′-CAGGAGGAGACCCCATGTGAC-3′ 5′-CCTCCACCCTGTTCAGCCC-3′
AGT 
M235T
5′-CAGGGTGCTGTCCACACTGGACCCC-3′ 5′-CCGTTTGTGCAGGGCCTGGCTCTCT-3′
AGT 
T704C
5′-CAGGGTGCTGTCCACACTGGACCCC-3′ 5′-CCGTTTGTGCAGGGCCTGGCTCTCT-3′
PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
Table 5. 
Primer sequences used in PCR for RAAS gene polymorphisms.
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